These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22243485)

  • 1. NcoI TNF-β gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; van Zoest KP; Moons LM; Hansen B; Pot RG; Siersema PD; Kusters JG; Kuipers EJ
    Scand J Gastroenterol; 2012 Apr; 47(4):378-86. PubMed ID: 22243485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myo9B is associated with an increased risk of Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; Van Zoest KP; Moons LM; Pot RG; Siersema PD; Kuipers EJ; Kusters JG
    Scand J Gastroenterol; 2012 Dec; 47(12):1422-8. PubMed ID: 22954106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
    Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
    Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
    von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
    Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; Pot RG; Moons LM; van Zoest KP; Hansen B; van Dekken H; Siersema PD; Kusters JG; Kuipers EJ
    J Hum Genet; 2012 Jan; 57(1):26-32. PubMed ID: 22129558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of malignant potential in reflux disease: are cytokine polymorphisms important?
    Gough MD; Ackroyd R; Majeed AW; Bird NC
    Am J Gastroenterol; 2005 May; 100(5):1012-8. PubMed ID: 15842572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in tumor necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China.
    Guo W; Wang N; Li Y; Zhang JH
    Chin Med J (Engl); 2005 Nov; 118(22):1870-8. PubMed ID: 16313841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptionally active human papillomavirus is strongly associated with Barrett's dysplasia and esophageal adenocarcinoma.
    Rajendra S; Wang B; Snow ET; Sharma P; Pavey D; Merrett N; Ball MJ; Brain T; Fernando R; Robertson IK
    Am J Gastroenterol; 2013 Jul; 108(7):1082-93. PubMed ID: 23588239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma.
    Murphy SJ; Hughes AE; Patterson CC; Anderson LA; Watson RG; Johnston BT; Comber H; McGuigan J; Reynolds JV; Murray LJ
    Carcinogenesis; 2007 Jun; 28(6):1323-8. PubMed ID: 17277236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence.
    McElholm AR; McKnight AJ; Patterson CC; Johnston BT; Hardie LJ; Murray LJ;
    Gastroenterology; 2010 Jul; 139(1):204-12.e3. PubMed ID: 20403354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma.
    Moons LM; Kuipers EJ; Rygiel AM; Groothuismink AZ; Geldof H; Bode WA; Krishnadath KK; Bergman JJ; van Vliet AH; Siersema PD; Kusters JG
    Am J Gastroenterol; 2007 Nov; 102(11):2373-9. PubMed ID: 17581270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.